###### Strengths and limitations of this study

-   This multi-site evaluation in routine clinical care suggests that emotion regulation group therapy may be an easily disseminated and useful treatment for deliberate self-harm.

-   Participants reported continued reductions in deliberate self-harm after treatment conclusion.

-   This study lacked a control group, limiting our ability to draw conclusions about the effectiveness of emotion regulation group therapy specifically.

-   As only adult women were included in the study, generalisability to other patient populations is unclear.

Introduction {#s1}
============

Deliberate self-harm (DSH; also referred to as non-suicidal self-injury) is defined as 'the deliberate, direct destruction or alteration of body tissue without conscious suicidal intent, but resulting in injury severe enough for tissue damage (eg, scarring) to occur'.[@R1] DSH is highly prevalent in both clinical and non-clinical adult and adolescent populations[@R2] and is particularly common among individuals with borderline personality disorder (BPD[@R5]). DSH has been implicated in the high levels of healthcare utilisation among individuals with BPD[@R7] and is one of the strongest predictors of future suicide attempts.[@R8]

Although the past 2 decades have seen the development of several efficacious treatments for DSH within BPD, including dialectical behaviour therapy (DBT[@R6]), mentalisation-based treatment[@R10] and emotion regulation group therapy (ERGT[@R11]), few studies have evaluated these treatments in traditional clinical settings (for exceptions, see Bales *et al*, Feigenbaum *et al*, Pasieczny *et al*, Wagner *et al*[@R13]), and the extent to which they can be disseminated to community clinicians remains unclear.[@R17] Indeed, although efficacy trials are imperative for establishing the evidence base of a treatment, they often maximise internal validity, specialised training and experimental controls at the cost of external validity and applicability to traditional clinical settings.[@R18] Trials of treatments provided in routine clinical settings, on the other hand, can evaluate how a treatment works under more real-world conditions and, as such, contribute important information about the utility and feasibility of a treatment in traditional clinical settings. These trials also play an important role in increasing the availability of evidence-based treatments.[@R20] Thus, further research examining the utility of empirically supported treatments for DSH within BPD in real-world clinical settings is needed.

This study sought to examine the utility of one such treatment in a nationwide open trial. Specifically, in an effort to increase the availability of clinically feasible treatments for DSH in BPD within the community, we conducted an evaluation of ERGT (a 14-week adjunctive group treatment with established efficacy in the treatment of DSH within BPD[@R12]) in routine clinical care, as delivered by community clinicians at 14 psychiatric outpatient clinics throughout Sweden. Consistent with past research on ERGT, we expected to find significant improvements from pretreatment to post-treatment in DSH and other self-destructive behaviours, emotion dysregulation, psychiatric symptoms and adaptive functioning, as well as stability of these improvements during the 6-month follow-up period.

Materials and methods {#s2}
=====================

Design and participants {#s2a}
-----------------------

The present trial was conducted at 14 psychiatric outpatient clinics located throughout Sweden. We used an uncontrolled open trial design with a 6-month follow-up.

Participants were recruited and assessed by community-based healthcare professionals at the psychiatric outpatient clinics. To ensure comparability of the findings to previous ERGT trials, the inclusion criteria in this study were similar to those used in earlier ERGT studies.[@R11] Eligibility criteria included: (a) being a woman ≥18 years, (b) meeting ≥3 diagnostic criteria for BPD as determined by the Structured Clinical Interview for DSM-IV Personality Disorders (SCID-II[@R21]), (c) ≥3 episodes of DSH in the past 6 months as assessed by a clinician-administered interview version of the Deliberate Self-Harm Inventory (DSHI[@R1]), (d) ongoing treatment as usual in the community and (e) stability of psychotropic medications for at least 2 months before inclusion. Exclusion criteria were minimal and included only: (a) a DSM-IV[@R22] diagnosis of psychotic or bipolar I disorder or ongoing (past month) substance dependence as assessed with the MINI International Neuropsychiatric Interview (MINI 6[@R23]), (b) the presence of co-occurring psychiatric disorders that required immediate treatment (eg, anorexia nervosa), (c) insufficient understanding of the Swedish language and (d) current life circumstances that would interfere with treatment (ie, being homeless). The study was approved by the Regional Ethical Review Board in Stockholm (Dnr 2013/1321-31/3) and was registered on Clinicaltrials.gov (Identifier NCT01986257). Due to an administrative error, the study was not released on the Clinical Trials platform by the principal investigator, until November 4, 4 weeks after the first patient was included. At that date, one group had had one ERGT session and another group had had two ERGT sessions, but there were no changes in the study protocol at any time between the start of inclusion of patients and the release of the protocol.

Between October 2013 and March 2014, 108 female participants with threshold or subthreshold BPD were considered for participation in the study. All participants provided written informed consent. Eight participants did not meet inclusion criteria, four dropped out before completing the pretreatment assessment and one completed the pretreatment assessment but died from suicide before beginning ERGT. Thus, the final sample size was 95 participants. Diagnostic and demographic data for the final sample are presented in [table 1](#T1){ref-type="table"}. Notably, this sample was comparable to those of both past ERGT trials and other BPD treatment outcome studies with regard to both demographic characteristics and co-occurring psychiatric disorders.[@R12] Participant flow through the trial is described in [figure 1](#F1){ref-type="fig"}.

![Participant flow through the study. BPD, borderline personality disorder; DSH, deliberate self-harm; ERGT, emotion regulation group therapy.](bmjopen-2017-016220f01){#F1}

###### 

Sociodemographic, clinical and diagnostic data of the sample (n=95)

  Variable                                   n    (%)      Mean   SD     Range
  ------------------------------------------ ---- -------- ------ ------ --------
  Age                                                      25.1   7.0    18--49
  Educational level                                                      
  Primary school                             27   (28.4)                 
  High school/vocational school              58   (61.1)                 
  University                                 10   (10.5)                 
  Marital status                                                         
  Single                                     26   (27.3)                 
  Married/cohabiting                         24   (25.3)                 
  Living with children                       16   (16.8)                 
  Occupational status                                                    
  Full-time student                          37   (39.0)                 
  Employed                                   24   (25.3)                 
  Unemployed                                 21   (22.1)                 
  On disability pension                      13   (13.7)                 
  On temporary sick leave                    24   (25.3)                 
  Clinical characteristics                                               
  Meeting full diagnostic criteria for BPD   65   (68.0)                 
  Number of threshold BPD criteria                         5.2    1.5    
  Suicide attempt, lifetime\*                54   (58.1)                 1--50
  Suicide attempt, past 3 months\*           18   (17.2)                 1--4
  DSH frequency past 6 months                              61.4   83.3   
  Rate of psychiatric medication use         68   (71.6)                 
  Number of psychiatric medications                        1.9    1.8    
  Rate of previous psychiatric treatment     80   (84.2)                 
  Months of ongoing treatment                              12.0   34.6   
  Type of ongoing treatment                                              
  Cognitive behavioural therapy              30   (31.6)                 
  Psychodynamic therapy                      10   (10.5)                 
  Supportive therapy                         45   (47.4)                 
  Other                                      10   (10.5)                 
  Co-occurring psychiatric disorders                                     
  Depression                                 51   (53.7)                 
  Panic disorder                             36   (37.9)                 
  Social anxiety disorder                    36   (37.9)                 
  Post-traumatic stress disorder             20   (21.1)                 
  Generalised anxiety disorder               38   \(40\)                 
  Eating disorder                            15   (15.8)                 
  Substance use disorders                    4    (4.2)                  

BPD, borderline personality disorder; DSH, deliberate self-harm.

\*There were data missing for two participants on history of attempted suicide (n=93).

Selection of participating clinics and study therapists {#s2b}
-------------------------------------------------------

An invitation to participate in the study was distributed through a national network of psychiatric caregivers (with representatives from all county councils). Thirty-two clinics responded to the invitation, from which 15 clinics were selected. All participating clinics had to have at least one employed therapist meeting the following criteria: (a) educated within a regulated profession (eg, a licensed nurse, psychologist or psychotherapist) and (b) basic training in cognitive behavioural therapy (with training in acceptance and commitment therapy (ACT) and/or DBT preferred). Consideration was also given to the clinics' geographical location, aiming for as broad a national geographical representation as possible. One included clinic did not participate in the study due to local administrative difficulties, leaving 14 clinics and 28 therapists in the study. Across these clinics, a total of 17 groups were conducted. Median number of participants treated at each clinic was seven (IQR: 5--9; min 4, max 11). The clinics were located in 9 cities (population size range: 33 155--2 136 042, median 101 615.5[@R26]).

To compensate for the extra cost of implementing a new treatment within the context of regular care, the clinics received monetary compensation for administration of ERGT at a value of US\$1800 per group.

Assessments {#s2c}
-----------

Clinician-administered assessments at baseline included the BPD module of SCID-II,[@R21] an interview version of DSHI,[@R1] MINI 6[@R23] and the Columbia-Suicide Severity Rating Scale.[@R27] Treatment outcome measures were administered in self-report format at baseline, pretreatment, post-treatment and 6-month follow-up. All self-report measures used in the study were completed online (a method with demonstrated validity[@R28]).

The primary outcome measure was the total frequency of DSH measured by DSHI, a self-report measure with adequate test--retest reliability and construct, discriminant and convergent validity.[@R1] DSHI specifies 16 different types of DSH (eg, cutting, burning or hitting oneself). DSHI was also used to assess DSH versatility (ie, number of different types of DSH behaviours in the past 4 months)---an index of DSH severity.[@R29]

The secondary outcome measures included the following self-report measures: the Difficulties in Emotion Regulation Scale (DERS[@R30]), a measure of clinically relevant emotion regulation difficulties (α=0.90 in this sample) with good test--retest reliability and construct and predictive validity[@R20]; the 11-item self-destructive behaviour supplement to the Borderline Symptom List (BSL[@R32]), which assesses past week engagement in several self-destructive behaviours (eg, binge eating, excessive drinking, drug use, risky sexual behaviours); the 21-item Depression Anxiety Stress Scales,[@R33] a measure of depression, anxiety and stress symptoms (α=0.88 in this sample) with good test--retest reliability and construct and discriminant validity[@R33]; the BPD-related composite of the Inventory of Interpersonal Problems,[@R35] a measure of BPD-relevant interpersonal difficulties (α=0.89 in this sample) with good convergent validity and specificity[@R35]; and the Sheehan Disability Scales,[@R36] a widely used measure of social and vocational impairment due to psychological symptoms (α=0.80 in this sample) with adequate reliability and construct, convergent and discriminant validity across various clinical populations.[@R37] Treatment credibility and expectancy were assessed after the second session of ERGT with the Credibility/Expectancy Questionnaire.[@R39]

Treatment {#s2d}
---------

ERGT is a 14-session, adjunctive, acceptance-based behavioural group treatment developed to treat DSH by targeting its underlying mechanism of emotion dysregulation.[@R11] Based on Gratz and Roemer's[@R30] conceptualisation of emotion regulation, ERGT systematically teaches skills aimed at improving a number of dimensions of emotion regulation, including: emotional awareness, understanding and acceptance; the ability to control behaviours when experiencing negative emotions; the use of non-avoidant emotion regulation strategies to modulate the intensity and/or duration of emotional responses; and the willingness to experience negative emotions as part of pursuing meaningful activities in life. Moreover, the following themes are emphasised throughout the treatment: (a) the potentially paradoxical effects of emotional avoidance; (b) the emotion regulating consequences of emotional acceptance and willingness; and (c) the importance of controlling behaviour when emotions are present, rather than controlling emotions themselves. A detailed description of the content and development of ERGT is available elsewhere.[@R11]

The ERGT treatment manual (Gratz and Tull, 2010, unpublished manual) provides thorough instructions on the therapeutic stance and theoretical framework of ERGT, as well as detailed descriptions of the content, in-session exercises and homework assignments for each session. Sudden deterioration or suicidal crises are monitored weekly through self-report measures assessing DSH frequency and emotion dysregulation and addressed by the group therapists in collaboration with the ongoing treatment provider if needed. The ERGT treatment manual was translated into Swedish through a collaborative and iterative process involving the treatment developer (KLG) and co-author of the ERGT manual (MTT) and the primary ERGT supervisors for this trial (HS and JB, in collaboration with LGL). In this trial, ERGT was delivered in weekly 2-hour sessions led by two therapists with groups of 4--9 participants (average group size=5.59).

Therapist training and treatment fidelity {#s2e}
-----------------------------------------

Prior to the trial, therapists were required to study the ERGT manual and relevant articles on the theoretical underpinnings of ERGT, as well as to participate in a 3-day workshop led by the authors of the ERGT manual (KLG and MTT). The workshop consisted of didactic lectures, demonstrations, role playing and practice exercises. Of the 28 therapists, 22 were licensed psychologists, 2 were social workers, 2 were nurses, 1 was a psychiatric aid and 1 was an occupational therapist. Twenty-six therapists had previous experience treating patients with BPD and/or DSH; 3 therapists had previous experience with ACT, and 19 therapists had experience with DBT. To ensure treatment fidelity during the ERGT trial, all sessions were filmed and reviewed weekly by clinicians with experience delivering ERGT (HS, JB), and all therapists received the option of weekly supervision based on the reviewed films.

Statistics and data analysis {#s2f}
----------------------------

We expected to recruit 90--105 participants. This sample size yielded high power (\>0.99 with α=0.05) to detect a standardised mean difference between pretreatment and post-treatment of d=0.5 using within-group Student's t-tests on a log-transformation of the primary outcome measure DSH frequency (consistent with past research on ERGT[@R11]).

All analyses were performed in R using random effects modelling.[@R40] The count variables, DSH frequency and BSL, are reported with medians and IQR and were analysed using negative binomial generalised mixed models, and the remaining continuous outcomes are reported as means and SD and were analysed using linear models. The models included all available data at the three assessment points (pretreatment, post-treatment and 6-month follow-up) for each outcome, thus making them intent-to-treat analyses. We estimated separate slopes for the change between the pretreatment and post-treatment assessments (S1) and the change between the post-treatment and 6-month follow-up assessments (S2). Random intercepts and random slopes as well as autoregressive correlation structures were included in the models if they significantly improved model fit according to log-likelihood ratio tests.

Effect sizes were calculated for changes between pretreatment, post-treatment and 6-month follow-up. For the count variables (ie, DSHI frequency and BSL), the percentage change from baseline to any subsequent time point with 95% CI was used as an effect size. This was calculated by exponentiating the estimate for the slopes derived from the negative binomial models and interpreting the range below or above 1 as the percentage decrease or increase in the outcome for a 1-unit increase in the predictor. Effect sizes for the remaining continuous outcomes are reported as Cohen's d, calculated by dividing the appropriate slope estimate (ie, pretreatment to post-treatment: S1; pretreatment to 6-month follow-up: S1+S2; and post-treatment to 6-month follow-up: S2) by the pretreatment SD. We also performed separate analyses where linear mixed models were applied to log-transformed DSH frequency and BSL scores and corresponding effect sizes were extracted. These effect sizes are reported together with observed means and SD of DSH frequency and BSL scores to permit comparison with previous studies of ERGT.[@R11] However, inferences of the statistical significance of changes on these measures were based on the more appropriate negative binomial regression models. CIs with a 95% margin for the effect sizes were calculated using 5000 bootstrap replications.[@R41] The bootstrap replications were clustered on participants.[@R42]

We also performed sensitivity analyses to investigate the robustness and validity of the DSHI results. First, the treating clinics were entered as random factors to test the possibility of clustering effects in the data. Second, we added concurrent medication status (coded as 0 for no concurrent medication and 1 for concurrent medication) and type of treatment as usual (coded as a factor with the following levels: cognitive behavioural therapy, psychodynamic therapy, supportive therapy or other) as covariates in the model. These covariates were added both as simple effects and as interaction effects with the S1 variable to investigate the possible influence of the covariates on DSH frequency and treatment effect. Third, we entered the number of treatment sessions attended as a predictor of improvement in DSH frequency during the treatment period.

Finally, we examined the number of participants who reported no (zero) DSH episodes at each assessment point and used McNemar's exact tests to analyse the changes between the assessment points.

Results {#s3}
=======

Treatment adherence and attrition {#s3a}
---------------------------------

The average time from baseline assessment to the start of treatment was 20.7 days (SD=17.2, range 1--91). Twenty-one participants (22%) dropped out of ERGT (see [figure 1](#F1){ref-type="fig"}). Mean number of sessions attended for all included participants was 11 (SD=5.2, min 0, max 16). Seventy-two participants (76%) attended ≥7 sessions, and 47 (49%) attended 14 sessions. Post-treatment assessments were completed by 88 (93%) participants, and 6-month follow-up assessments were completed by 76 (82%) participants. Mean ratings of treatment credibility and expectancy completed after the second session were 5.7 (SD=1.8) and 47.0% (SD=25.5), respectively (for comparison, mean ratings reported by Gratz and Tull were 6.91% and 57%, respectively).[@R20]

Primary outcome {#s3b}
---------------

Results for both the primary and secondary outcome measures are displayed in [table 2](#T2){ref-type="table"}. There was a significant 52% reduction in DSH frequency from pretreatment to post-treatment and a 76% reduction from pretreatment to 6-month follow-up.

###### 

Treatment outcome variables for count and continuous outcomes at pretreatment, post-treatment and 6-month follow-up 

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome\       Pretreatment          Post-treatment        6-Month follow-up    Pretreatment to post-treatment comparison   Post-treatment to 6-month follow-up comparison   Pretreatment to 6-month follow-up comparison   Model *p^a^*                                   
  *Count data*                                                                                                                                                                                                                                                               
  -------------- --------------------- --------------------- -------------------- ------------------------------------------- ------------------------------------------------ ---------------------------------------------- ---------------- ------------ ---------------- ---------
  DSHI-f         22.00 (9.5 to 56.0)   10.00 (2.8 to 45.5)   4.00 (0.0 to 13.0)   4.24\*\*\*                                  52% (33 to 66)                                   3.62\*\*\*                                     49% (27 to 65)   7.33\*\*\*   76% (65 to 83)   \<0.001

  BSL            4.00 (2.0 to 7.0)     2.00 (1.0 to 5.0)     2.00 (0.3 to 5.0)    3.60\*\*\*                                  29% (14 to 41)                                   0.76                                           8% (−14 to 25)   4.18\*\*\*   34% (20 to 46)   \<0.001
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome\            Pretreatment     Post-treatment   6-Month follow-up   Pretreatment to post-treatment comparison   Post-treatment to 6-month follow-up comparison   Pretreatment to 6-month follow-up comparison   Model *p^a^*                                              
  *Continuous data*                                                                                                                                                                                                                                                               
  ------------------- ---------------- ---------------- ------------------- ------------------------------------------- ------------------------------------------------ ---------------------------------------------- ---------------------- ------------ --------------------- ---------
  DSHI-v              3.01 (1.82)      2.23 (2.02)      1.67 (1.76)         3.67\*\*\*                                  0.41 (0.19 to 0.63)                              2.86\*\*                                       0.24 (0.07 to 0.42)    5.65\*\*\*   0.65 (0.40 to 0.89)   \<0.001

  DERS                125.98 (19.37)   108.17 (27.52)   104.66 (27.40)      6.56\*\*\*                                  0.91 (0.63 to 1.20)                              1.00                                           0.12 (−0.09 to 0.43)   7.13\*\*\*   1.03 (0.69 to 1.38)   \<0.001

  IIP-BPD             2.05 (0.72)      1.98 (0.71)      1.78 (0.76)         1.08                                        0.10 (−0.06 to 0.29)                             2.43\*                                         0.24 (0.06 to 0.43)    3.46\*\*\*   0.34 (0.13 to 0.59)   0.002

  DASS-D              25.35 (10.28)    20.11 (11.80)    19.95 (11.92)       4.37\*\*\*                                  0.50 (0.29 to 0.75)                              0.41                                           0.05 (−0.22 to 0.30)   3.91\*\*\*   0.55 (0.27 to 0.85)   \<0.001

  DASS-A              17.14 (8.98)     16.30 (9.97)     14.54 (9.58)        0.85                                        0.08 (−0.10 to 0.27)                             1.59                                           0.17 (−0.05 to 0.41)   2.11\*       0.25 (0.01 to 0.49)   0.024

  DASS-S              25.77 (7.95)     23.34 (9.21)     21.19 (10.34)       2.46\*                                      0.30 (0.06 to 0.54)                              1.95\*                                         0.26 (0.01 to 0.52)    4.30\*\*\*   0.56 (0.26 to 0.86)   \<0.001

  SDS                 18.44 (6.99)     18.59 (7.05)     16.01 (8.41)        −0.25                                       −0.03 (−0.22 to 0.16)                            2.71\*\*                                       0.32 (0.07 to 0.60)    2.51\*       0.29 (0.04 to 0.59)   0.013
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Test statistics are based on negative binomial generalised mixed models for count data and linear mixed models analyses for continuous data. CIs for effect sizes are based on 5000 bootstrap replications.

BSL, Borderline Symptom List, behaviour supplement; DASS-A, Depression Anxiety and Stress Scales-21 Anxiety; DASS-D, Depression Anxiety and Stress Scales-21 Depression; DASS-S, Depression Anxiety and Stress Scales-21 Stress; DERS, Difficulties in Emotion Regulation Scale; DSHI-f, Deliberate Self-Harm Inventory-frequency; DSHI-v, Deliberate Self-Harm Inventory-versatility; IIP-BPD, BPD-related composite of the Inventory of Interpersonal Problems; SDS, Sheehan Disability Scales.

(*p-*value of log-likelihood ratio comparison with null model including no fixed effects and only random intercept)

\*p\<.05 \*\*p\<0.01, \*\*\*p\<0.001.

†Effect size estimates for DSHI frequency and BSL are reported as per cent change across time, and effect sizes for the remaining continuous outcomes are reported as Cohen's d.

The observed means for DSH frequency were 53.68 (SD=99.88), 37.45 (SD=72.22) and 28.69 (SD=95.44) at pretreatment, post-treatment and follow-up, respectively. Effect sizes (Cohen's d) based on log-transformed data showed medium-sized reductions in DSH frequency from pretreatment to post-treatment (d=0.52, 95% CI 0.30 to 0.75) and from post-treatment to 6-month follow-up (d=0.47, 95% CI 0.27 to 0.70). A large effect size was observed from pretreatment to 6-month follow-up (d=0.99, 95% CI 0.70 to 1.30).

The percentage of participants with an observed score of zero DSH episodes during the past 4 months increased significantly from 4.2% at pretreatment to 17.9% at post-treatment (Exact McNemar's χ^2^=12.25, df=1, p\<0.001) and to 25.3% at follow-up (Exact McNemar's χ^2^=16.67, df=1, p\<0.001). The increase between post-treatment and follow-up was also significant (Exact McNemar's χ^2^=7.14, df=1, p=0.01).

Secondary outcomes {#s3c}
------------------

There were significant improvements in DSH versatility, emotion dysregulation, self-destructive behaviours and depression and stress symptoms at post-treatment, accompanied by small to large effect sizes (see [table 2](#T2){ref-type="table"}). At the 6-month follow-up, all of these improvements were either maintained or further improved on, with the change on DERS from pretreatment to 6-month follow-up reaching a large-sized effect. Median reduction in self-destructive behaviours over each time period is reported in [table 2](#T2){ref-type="table"}. The observed mean self-destructive behaviour scores were 4.82 (SD=3.69), 3.65 (SD=4.24) and 3.24 (SD=3.61) at pretreatment, post-treatment and follow-up, respectively. Analyses on log-transformed data showed small to medium effect sizes between pretreatment and post-treatment (Cohen's d=0.43, 95% CI 0.20 to 0.65) and pretreatment and 6-month follow-up (d=0.55, 95% CI 0.27 to 0.77). Improvements in interpersonal difficulties, anxiety and social and vocational impairment were not significant at post-treatment; however, at 6-month follow-up, there were significant improvements in these outcomes (accompanied by small to moderate effect sizes) from pretreatment (stemming from the additional significant improvements in these measures observed from post-treatment to 6-month follow-up).

Sensitivity analyses {#s3d}
--------------------

First, we included the treating clinics as random factors in the DSH frequency model. This did not improve model fit, suggesting that there was not a significant clustering effect of treating clinic in the data. Second, we included concurrent medication status and type of treatment as usual as simple effects and interaction effects with S1 (ie, the change between the pretreatment and post-treatment assessments) in the DSH frequency model. None of the added predictors were statistically significant (p\>0.05), suggesting that concurrent medication use and type of treatment as usual were not associated with treatment effect. Third, we included the number of attended sessions as a predictor of improvement in DSH frequency. The interaction effect between session count and S1 was statistically significant, (B=0.06, Z=11.54, p\<0.001), indicating that higher attendance was associated with larger improvements during treatment.

Discussion {#s4}
==========

The present multi-site evaluation of ERGT in routine clinical care provides additional support for the feasibility and transportability of this treatment. Results revealed significant improvements in DSH frequency and versatility, emotion dysregulation, self-destructive behaviours and depression and stress symptoms from pretreatment to post-treatment. By the 6-month follow-up, interpersonal difficulties and social and vocational impairment had also improved significantly. Moreover, all gains found at post-treatment were either maintained or further improved on at follow-up. Notably, the results of the sensitivity analyses strengthen our confidence in these findings, providing evidence of a significant effect of session attendance, but not treatment clinic, concurrent medication use or type of treatment as usual, on improvements in DSH frequency. These results are consistent with past findings that characteristics of participants' ongoing therapy in the community had minimal impact on treatment response to ERGT[@R43] and suggest that it is engagement in ERGT rather than other (non-specific) treatment-related factors that influences reductions in DSH frequency. Nonetheless, the uncontrolled open trial design precludes conclusions regarding the causal relation of treatment participation to symptom improvement as there may be other factors underlying both treatment completion status and symptom improvement (ie, motivation for treatment or alliance with treatment providers) that may, at least in part, account for the present findings.

Although the results of this study need to be interpreted with caution (due to the lack of a control group), they are similar to those obtained in previous ERGT efficacy trials.[@R11] Likewise, our findings of either stability or further improvements during the follow-up period are consistent with the observed pattern of continued or maintained improvement during a 9-month follow-up period in Gratz and colleagues' randomised controlled trial (RCT).[@R12] These findings provide further support for the durability of improvements following this relatively brief and non-intensive treatment, suggesting that participants may experience durable gains through ERGT even when delivered by community clinicians with only brief training in this treatment.

Despite these similarities with previous ERGT trials, the pattern of findings for measures of interpersonal, social and vocational functioning differed from Gratz and colleagues' previous ERGT studies.[@R12] Specifically, results revealed no significant changes in interpersonal difficulties or social and vocational impairment from pretreatment to post-treatment, although there were significant (although small) improvements in these areas during the follow-up period. Although the differences in these findings may be due to study-related differences in therapist training and/or treatment delivery, they may also be explained (in part) by the fact that more than one-third of participants (39%) in the present trial were on disability pension or current sick leave, thus limiting their social interactions and vocational opportunities during treatment.

Notably, rates of abstinence from DSH increased significantly from pretreatment to post-treatment, as well as from post-treatment through the 6-month follow-up, with 25.2% of participants reporting abstinence from DSH 6 months post-treatment. Nonetheless, it warrants mention that the proportion of participants reaching abstinence from DSH was lower than in previous ERGT trials.[@R12] This may be due to differences in the level of training and supervision provided in this trial versus previous trials. Indeed, ratings of treatment credibility and expectancy in this trial were somewhat lower than in previous studies of ERGT, potentially capturing the lesser experience of the therapists in this trial. Conversely, the lower rate of treatment-related abstinence from DSH observed in this study may reflect differences in sample composition and/or clinical severity (as both emotion dysregulation and DSH frequency reported in this sample were at the high end of the range reported in past ERGT studies). Nonetheless, past research examining predictors of treatment response to ERGT found that several indicators of greater severity in domains relevant to ERGT (ie, baseline emotion dysregulation and BPD criteria, lifetime and recent DSH, and past-year hospitalisation and suicide attempts) predicted *better* responses during treatment and follow-up,[@R43] suggesting that greater severity in certain domains may be associated with better response to this treatment. Future research is needed to clarify the particular patients most likely to benefit from ERGT.

Importantly, we found significant reductions across all assessment points in DSH versatility (ie, a marker of DSH severity associated with future suicide risk).[@R29] This finding lends support to the potential utility of ERGT in decreasing risk for self-injurious behaviours in general. Indeed, given the high occurrence of DSH and suicidal behaviours,[@R9] as well as evidence that DSH is one of the strongest prospective predictors of future suicide attempts,[@R44] the emphasis within ERGT on reducing DSH could be expected to reduce suicidal risk as well. Nonetheless, in the absence of data in this or previous ERGT trials on suicidal outcomes in particular, the benefits of ERGT for suicidality remain unknown and in need of future investigation.

Although results of this study provide preliminary support for the utility of ERGT in routine clinical care, they also highlight more broadly the potential utility of targeting emotion dysregulation in the treatment of BPD-related pathology. Notably, there are several other empirically supported treatments for BPD and related pathology that directly target emotion dysregulation, including DBT[@R6] and Systems Training for Emotional Predictability and Problem Solving.[@R46] Findings of the efficacy of those treatments for BPD,[@R24] combined with both the results of the current study and past findings supporting the efficacy of ERGT for DSH within BPD,[@R11] highlight the potential benefits of interventions aimed at promoting adaptive emotion regulation among individuals with BPD and provide further support for emotion dysregulation as a primary mechanism underlying the pathogenesis and effective treatment of BPD and related pathology.[@R48]

There are several strengths of this study that are worth noting. First, the naturalistic design of this study permitted inclusion of a large sample of participants who received this ERGT as part of their standard treatment. Second, data attrition was low (8% at post-treatment and 18% at follow-up) and participant dropout was within expected levels when treating individuals with BPD[@R49] and consistent with previous ERGT trials.[@R12] Third, contrary to previous ERGT trials,[@R11] the group leaders were of different professional backgrounds and representative of the community clinicians who regularly treat this patient population, providing support for the generalisability and transportability of this treatment. Finally, our data provide support for the feasibility of disseminating ERGT to community clinicians, as therapists in this study were provided with only readings and a brief workshop on ERGT prior to its delivery.

Despite these strengths, findings must be considered in light of limitations present. First, the lack of a control condition precludes conclusions about the effects of this ERGT (vs treatment as usual or the passage of time). However, it is important to note that the waitlist conditions in previous ERGT trials generally evidenced stability over time on all measures of interest (likely due to the relatively short time-frame of the treatment period). Nonetheless, future studies are needed to evaluate the effectiveness of ERGT within an RCT design. Second, even though the participating clinicians were offered weekly supervision based on filmed sessions, no systematic adherence ratings were conducted. This limits our ability to speak to the quality of ERGT and its relation to outcome. Third, the results relied solely on self-report measures and not clinician-rated outcomes. However, research on self-reported versus clinician-rated outcomes in psychotherapy studies suggests that the use of self-report measures often results in smaller effect sizes when compared with clinician-administered instruments.[@R50] Thus, it is possible that our results may be conservative estimates of improvements during and after treatment. Fourth, our study only included women, which limits the generalisability of the results to men. Future research is needed that evaluates ERGT within male or mixed-gender samples. Finally, current (past month) substance dependence was an exclusion criterion in this study, both to ensure comparability with previous ERGT trials and because active substance dependence requires specialised treatment and a higher level of care. Indeed, in Sweden, individuals with ongoing substance dependence are not necessarily offered treatment within a psychiatric clinic; rather, they may be referred to specialised substance dependence treatment centres. Thus, it is unlikely that the exclusion of such individuals negatively affected the generalisability of this sample to a typical Swedish psychiatric clinic. Furthermore, this criterion did not exclude individuals with past (or even recent) substance use problems. Nonetheless, given the high co-occurrence of substance dependence and BPD,[@R51] excluding these individuals may have limited the external validity of the sample to patients with BPD as a whole.

Despite these limitations, our results provide further evidence for the utility and transportability of ERGT, suggesting that this is a feasible treatment for DSH, emotion dysregulation and psychiatric symptoms when delivered by community clinicians in traditional clinical settings.
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